News

Sarepta, Replimmune, Capricor rise as FDA’s biologics head departs
Replimune (NASDAQ:REPL), and Capricor Therapeutics (NASDAQ:CAPR), which faced regulatory setbacks from the FDA’s biologics ...
Replimune (REPL) Faces Securities Class Action Following Stock's Collapse Amid FDA's Rejection Of Melanoma Drug - Hagens Berman
The lawsuit comes after Replimune investors witnessed a 77% collapse in the price of their shares on July 22 when the company announced that the Food and Drug Administration (FDA) had rejected its ...
Sport.co.uk8d
Transfer rumors, news: Liverpool turn to Gordon as Diaz replacement
Liverpool are looking to re-ignite interest in Newcastle winger Anthony Gordon if Luis Díaz leaves this summer. Transfe ...
REPL Investors Have Opportunity to Lead Replimune Group, Inc. Securities Fraud Lawsuit with the Schall Law Firm
Detailed price information for Replimune Group Inc (REPL-Q) from The Globe and Mail including charting and trades.
Replimune (REPL) Shares Plummet After FDA Rejects Melanoma Drug, Sparking Investor Concerns - Hagens Berman
The market reacted swiftly, sending the price of Replimune shares crashing 77% lower on unusually high volume on July 22, 2025. “We're investigating whether Replimune may have misled investors about ...
Developer Tech10d
Python 3.14 slithers closer with RC1 arrival
The Python development team has announced the arrival of 3.14's first release candidate before its official launch in October ...
Investor's Business Daily on MSN11d
Why Replimune's Surprise Rejection Rattled Wall Street, And Cratered Its Stock
Replimune stock cratered Tuesday after the Food and Drug Administration unexpectedly rejected its experimental melanoma ...
Replimune: A Surprise CRL Exposes Fragility Of The Melanoma Program
Replimune Group, Inc. faces FDA setbacks with RP1, raising financial risks and dilution concerns. Click here to find out why ...